Global PDE-3 Inhibitors Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Description

According to our (Global Info Research) latest study, the global PDE-3 Inhibitors market size was valued at US$ 675 million in 2024 and is forecast to a readjusted size of USD 919 million by 2031 with a CAGR of 4.6% during review period. 
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.,PDE-3 inhibitors are a class of drugs that inhibit phosphodiesterase-3 activity, thereby increasing intracellular cAMP levels in cardiac muscle cells, producing positive inotropic and vasodilatory effects. They are primarily used in the treatment of acute heart failure, cardiogenic shock, and certain peripheral vascular conditions. The upstream supply chain relies on high-purity active pharmaceutical ingredients (APIs) and fine chemical intermediates, largely produced by manufacturers in Europe, the U.S., and India, such as Lonza, Evonik, and Dr. Reddy's. Formulation requires high-quality excipients and strict sterile processing, with common excipients like lactose, hydroxypropyl methylcellulose, and microcrystalline cellulose supplied by global excipient leaders.

Downstream applications are concentrated in hospitals, particularly cardiology departments and intensive care units (ICUs), with end customers including large tertiary hospitals, specialized cardiac centers, and emergency care providers. With the rising global burden of cardiovascular diseases and the growing incidence of acute heart failure in aging populations, demand for PDE-3 inhibitors remains steady. However, their usage is somewhat constrained by potential side effects and competition from more advanced therapeutic alternatives.

In 2024, the global average price of PDE-3 inhibitors is approximately USD 5.7 per unit (with “unit” defined as either one oral tablet or one injection ampoule), and the total sales volume reaches about 115 million units.

This report is a detailed and comprehensive analysis for global PDE-3 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:
Global PDE-3 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global PDE-3 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global PDE-3 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global PDE-3 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PDE-3 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PDE-3 Inhibitors market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hikma Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Viatris, Otsuka Pharmaceutical, Sawai Pharmaceutical, Eurofarma, Italfarmaco, Korea United Pharm, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
PDE-3 Inhibitors market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Amrinone/Inamrinone
    Anagrelide
    Cilostazol
    Dipyridamole
    Milrinone
    Others

Market segment by Application
    Hospital
    Clinic
    Others

Major players covered
    Hikma Pharmaceuticals
    Takeda Pharmaceutical
    Teva Pharmaceutical
    Torrent Pharmaceuticals
    Viatris
    Otsuka Pharmaceutical
    Sawai Pharmaceutical
    Eurofarma
    Italfarmaco
    Korea United Pharm
    The Menarini Group
    Pfizer
    Sanofi
    Qilu Pharmaceutical
    Yabao Pharmaceuticals
    Lunan Better Pharmaceutical
    Yangtze River Pharmaceuticals

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PDE-3 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of PDE-3 Inhibitors, with price, sales quantity, revenue, and global market share of PDE-3 Inhibitors from 2020 to 2025.
Chapter 3, the PDE-3 Inhibitors competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PDE-3 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and PDE-3 Inhibitors market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of PDE-3 Inhibitors.
Chapter 14 and 15, to describe PDE-3 Inhibitors sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global PDE-3 Inhibitors Consumption Value by Type: 2020 Versus 2024 Versus 2031
        1.3.2 Amrinone/Inamrinone
        1.3.3 Anagrelide
        1.3.4 Cilostazol
        1.3.5 Dipyridamole
        1.3.6 Milrinone
        1.3.7 Others
    1.4 Market Analysis by Application
        1.4.1 Overview: Global PDE-3 Inhibitors Consumption Value by Application: 2020 Versus 2024 Versus 2031
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Others
    1.5 Global PDE-3 Inhibitors Market Size & Forecast
        1.5.1 Global PDE-3 Inhibitors Consumption Value (2020 & 2024 & 2031)
        1.5.2 Global PDE-3 Inhibitors Sales Quantity (2020-2031)
        1.5.3 Global PDE-3 Inhibitors Average Price (2020-2031)

2 Manufacturers Profiles
    2.1 Hikma Pharmaceuticals
        2.1.1 Hikma Pharmaceuticals Details
        2.1.2 Hikma Pharmaceuticals Major Business
        2.1.3 Hikma Pharmaceuticals PDE-3 Inhibitors Product and Services
        2.1.4 Hikma Pharmaceuticals PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.1.5 Hikma Pharmaceuticals Recent Developments/Updates
    2.2 Takeda Pharmaceutical
        2.2.1 Takeda Pharmaceutical Details
        2.2.2 Takeda Pharmaceutical Major Business
        2.2.3 Takeda Pharmaceutical PDE-3 Inhibitors Product and Services
        2.2.4 Takeda Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.2.5 Takeda Pharmaceutical Recent Developments/Updates
    2.3 Teva Pharmaceutical
        2.3.1 Teva Pharmaceutical Details
        2.3.2 Teva Pharmaceutical Major Business
        2.3.3 Teva Pharmaceutical PDE-3 Inhibitors Product and Services
        2.3.4 Teva Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.3.5 Teva Pharmaceutical Recent Developments/Updates
    2.4 Torrent Pharmaceuticals
        2.4.1 Torrent Pharmaceuticals Details
        2.4.2 Torrent Pharmaceuticals Major Business
        2.4.3 Torrent Pharmaceuticals PDE-3 Inhibitors Product and Services
        2.4.4 Torrent Pharmaceuticals PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.4.5 Torrent Pharmaceuticals Recent Developments/Updates
    2.5 Viatris
        2.5.1 Viatris Details
        2.5.2 Viatris Major Business
        2.5.3 Viatris PDE-3 Inhibitors Product and Services
        2.5.4 Viatris PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.5.5 Viatris Recent Developments/Updates
    2.6 Otsuka Pharmaceutical
        2.6.1 Otsuka Pharmaceutical Details
        2.6.2 Otsuka Pharmaceutical Major Business
        2.6.3 Otsuka Pharmaceutical PDE-3 Inhibitors Product and Services
        2.6.4 Otsuka Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.6.5 Otsuka Pharmaceutical Recent Developments/Updates
    2.7 Sawai Pharmaceutical
        2.7.1 Sawai Pharmaceutical Details
        2.7.2 Sawai Pharmaceutical Major Business
        2.7.3 Sawai Pharmaceutical PDE-3 Inhibitors Product and Services
        2.7.4 Sawai Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.7.5 Sawai Pharmaceutical Recent Developments/Updates
    2.8 Eurofarma
        2.8.1 Eurofarma Details
        2.8.2 Eurofarma Major Business
        2.8.3 Eurofarma PDE-3 Inhibitors Product and Services
        2.8.4 Eurofarma PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.8.5 Eurofarma Recent Developments/Updates
    2.9 Italfarmaco
        2.9.1 Italfarmaco Details
        2.9.2 Italfarmaco Major Business
        2.9.3 Italfarmaco PDE-3 Inhibitors Product and Services
        2.9.4 Italfarmaco PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.9.5 Italfarmaco Recent Developments/Updates
    2.10 Korea United Pharm
        2.10.1 Korea United Pharm Details
        2.10.2 Korea United Pharm Major Business
        2.10.3 Korea United Pharm PDE-3 Inhibitors Product and Services
        2.10.4 Korea United Pharm PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.10.5 Korea United Pharm Recent Developments/Updates
    2.11 The Menarini Group
        2.11.1 The Menarini Group Details
        2.11.2 The Menarini Group Major Business
        2.11.3 The Menarini Group PDE-3 Inhibitors Product and Services
        2.11.4 The Menarini Group PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.11.5 The Menarini Group Recent Developments/Updates
    2.12 Pfizer
        2.12.1 Pfizer Details
        2.12.2 Pfizer Major Business
        2.12.3 Pfizer PDE-3 Inhibitors Product and Services
        2.12.4 Pfizer PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.12.5 Pfizer Recent Developments/Updates
    2.13 Sanofi
        2.13.1 Sanofi Details
        2.13.2 Sanofi Major Business
        2.13.3 Sanofi PDE-3 Inhibitors Product and Services
        2.13.4 Sanofi PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.13.5 Sanofi Recent Developments/Updates
    2.14 Qilu Pharmaceutical
        2.14.1 Qilu Pharmaceutical Details
        2.14.2 Qilu Pharmaceutical Major Business
        2.14.3 Qilu Pharmaceutical PDE-3 Inhibitors Product and Services
        2.14.4 Qilu Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.14.5 Qilu Pharmaceutical Recent Developments/Updates
    2.15 Yabao Pharmaceuticals
        2.15.1 Yabao Pharmaceuticals Details
        2.15.2 Yabao Pharmaceuticals Major Business
        2.15.3 Yabao Pharmaceuticals PDE-3 Inhibitors Product and Services
        2.15.4 Yabao Pharmaceuticals PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.15.5 Yabao Pharmaceuticals Recent Developments/Updates
    2.16 Lunan Better Pharmaceutical
        2.16.1 Lunan Better Pharmaceutical Details
        2.16.2 Lunan Better Pharmaceutical Major Business
        2.16.3 Lunan Better Pharmaceutical PDE-3 Inhibitors Product and Services
        2.16.4 Lunan Better Pharmaceutical PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.16.5 Lunan Better Pharmaceutical Recent Developments/Updates
    2.17 Yangtze River Pharmaceuticals
        2.17.1 Yangtze River Pharmaceuticals Details
        2.17.2 Yangtze River Pharmaceuticals Major Business
        2.17.3 Yangtze River Pharmaceuticals PDE-3 Inhibitors Product and Services
        2.17.4 Yangtze River Pharmaceuticals PDE-3 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
        2.17.5 Yangtze River Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: PDE-3 Inhibitors by Manufacturer
    3.1 Global PDE-3 Inhibitors Sales Quantity by Manufacturer (2020-2025)
    3.2 Global PDE-3 Inhibitors Revenue by Manufacturer (2020-2025)
    3.3 Global PDE-3 Inhibitors Average Price by Manufacturer (2020-2025)
    3.4 Market Share Analysis (2024)
        3.4.1 Producer Shipments of PDE-3 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2024
        3.4.2 Top 3 PDE-3 Inhibitors Manufacturer Market Share in 2024
        3.4.3 Top 6 PDE-3 Inhibitors Manufacturer Market Share in 2024
    3.5 PDE-3 Inhibitors Market: Overall Company Footprint Analysis
        3.5.1 PDE-3 Inhibitors Market: Region Footprint
        3.5.2 PDE-3 Inhibitors Market: Company Product Type Footprint
        3.5.3 PDE-3 Inhibitors Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global PDE-3 Inhibitors Market Size by Region
        4.1.1 Global PDE-3 Inhibitors Sales Quantity by Region (2020-2031)
        4.1.2 Global PDE-3 Inhibitors Consumption Value by Region (2020-2031)
        4.1.3 Global PDE-3 Inhibitors Average Price by Region (2020-2031)
    4.2 North America PDE-3 Inhibitors Consumption Value (2020-2031)
    4.3 Europe PDE-3 Inhibitors Consumption Value (2020-2031)
    4.4 Asia-Pacific PDE-3 Inhibitors Consumption Value (2020-2031)
    4.5 South America PDE-3 Inhibitors Consumption Value (2020-2031)
    4.6 Middle East & Africa PDE-3 Inhibitors Consumption Value (2020-2031)

5 Market Segment by Type
    5.1 Global PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    5.2 Global PDE-3 Inhibitors Consumption Value by Type (2020-2031)
    5.3 Global PDE-3 Inhibitors Average Price by Type (2020-2031)

6 Market Segment by Application
    6.1 Global PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    6.2 Global PDE-3 Inhibitors Consumption Value by Application (2020-2031)
    6.3 Global PDE-3 Inhibitors Average Price by Application (2020-2031)

7 North America
    7.1 North America PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    7.2 North America PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    7.3 North America PDE-3 Inhibitors Market Size by Country
        7.3.1 North America PDE-3 Inhibitors Sales Quantity by Country (2020-2031)
        7.3.2 North America PDE-3 Inhibitors Consumption Value by Country (2020-2031)
        7.3.3 United States Market Size and Forecast (2020-2031)
        7.3.4 Canada Market Size and Forecast (2020-2031)
        7.3.5 Mexico Market Size and Forecast (2020-2031)

8 Europe
    8.1 Europe PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    8.2 Europe PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    8.3 Europe PDE-3 Inhibitors Market Size by Country
        8.3.1 Europe PDE-3 Inhibitors Sales Quantity by Country (2020-2031)
        8.3.2 Europe PDE-3 Inhibitors Consumption Value by Country (2020-2031)
        8.3.3 Germany Market Size and Forecast (2020-2031)
        8.3.4 France Market Size and Forecast (2020-2031)
        8.3.5 United Kingdom Market Size and Forecast (2020-2031)
        8.3.6 Russia Market Size and Forecast (2020-2031)
        8.3.7 Italy Market Size and Forecast (2020-2031)

9 Asia-Pacific
    9.1 Asia-Pacific PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    9.2 Asia-Pacific PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    9.3 Asia-Pacific PDE-3 Inhibitors Market Size by Region
        9.3.1 Asia-Pacific PDE-3 Inhibitors Sales Quantity by Region (2020-2031)
        9.3.2 Asia-Pacific PDE-3 Inhibitors Consumption Value by Region (2020-2031)
        9.3.3 China Market Size and Forecast (2020-2031)
        9.3.4 Japan Market Size and Forecast (2020-2031)
        9.3.5 South Korea Market Size and Forecast (2020-2031)
        9.3.6 India Market Size and Forecast (2020-2031)
        9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
        9.3.8 Australia Market Size and Forecast (2020-2031)

10 South America
    10.1 South America PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    10.2 South America PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    10.3 South America PDE-3 Inhibitors Market Size by Country
        10.3.1 South America PDE-3 Inhibitors Sales Quantity by Country (2020-2031)
        10.3.2 South America PDE-3 Inhibitors Consumption Value by Country (2020-2031)
        10.3.3 Brazil Market Size and Forecast (2020-2031)
        10.3.4 Argentina Market Size and Forecast (2020-2031)

11 Middle East & Africa
    11.1 Middle East & Africa PDE-3 Inhibitors Sales Quantity by Type (2020-2031)
    11.2 Middle East & Africa PDE-3 Inhibitors Sales Quantity by Application (2020-2031)
    11.3 Middle East & Africa PDE-3 Inhibitors Market Size by Country
        11.3.1 Middle East & Africa PDE-3 Inhibitors Sales Quantity by Country (2020-2031)
        11.3.2 Middle East & Africa PDE-3 Inhibitors Consumption Value by Country (2020-2031)
        11.3.3 Turkey Market Size and Forecast (2020-2031)
        11.3.4 Egypt Market Size and Forecast (2020-2031)
        11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
        11.3.6 South Africa Market Size and Forecast (2020-2031)

12 Market Dynamics
    12.1 PDE-3 Inhibitors Market Drivers
    12.2 PDE-3 Inhibitors Market Restraints
    12.3 PDE-3 Inhibitors Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of PDE-3 Inhibitors and Key Manufacturers
    13.2 Manufacturing Costs Percentage of PDE-3 Inhibitors
    13.3 PDE-3 Inhibitors Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 PDE-3 Inhibitors Typical Distributors
    14.3 PDE-3 Inhibitors Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global PDE-3 Inhibitors Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
 Table 2. Global PDE-3 Inhibitors Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Table 3. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 4. Hikma Pharmaceuticals Major Business
 Table 5. Hikma Pharmaceuticals PDE-3 Inhibitors Product and Services
 Table 6. Hikma Pharmaceuticals PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 7. Hikma Pharmaceuticals Recent Developments/Updates
 Table 8. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 9. Takeda Pharmaceutical Major Business
 Table 10. Takeda Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 11. Takeda Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 12. Takeda Pharmaceutical Recent Developments/Updates
 Table 13. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 14. Teva Pharmaceutical Major Business
 Table 15. Teva Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 16. Teva Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 17. Teva Pharmaceutical Recent Developments/Updates
 Table 18. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 19. Torrent Pharmaceuticals Major Business
 Table 20. Torrent Pharmaceuticals PDE-3 Inhibitors Product and Services
 Table 21. Torrent Pharmaceuticals PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 22. Torrent Pharmaceuticals Recent Developments/Updates
 Table 23. Viatris Basic Information, Manufacturing Base and Competitors
 Table 24. Viatris Major Business
 Table 25. Viatris PDE-3 Inhibitors Product and Services
 Table 26. Viatris PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 27. Viatris Recent Developments/Updates
 Table 28. Otsuka Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 29. Otsuka Pharmaceutical Major Business
 Table 30. Otsuka Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 31. Otsuka Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 32. Otsuka Pharmaceutical Recent Developments/Updates
 Table 33. Sawai Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 34. Sawai Pharmaceutical Major Business
 Table 35. Sawai Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 36. Sawai Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 37. Sawai Pharmaceutical Recent Developments/Updates
 Table 38. Eurofarma Basic Information, Manufacturing Base and Competitors
 Table 39. Eurofarma Major Business
 Table 40. Eurofarma PDE-3 Inhibitors Product and Services
 Table 41. Eurofarma PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 42. Eurofarma Recent Developments/Updates
 Table 43. Italfarmaco Basic Information, Manufacturing Base and Competitors
 Table 44. Italfarmaco Major Business
 Table 45. Italfarmaco PDE-3 Inhibitors Product and Services
 Table 46. Italfarmaco PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 47. Italfarmaco Recent Developments/Updates
 Table 48. Korea United Pharm Basic Information, Manufacturing Base and Competitors
 Table 49. Korea United Pharm Major Business
 Table 50. Korea United Pharm PDE-3 Inhibitors Product and Services
 Table 51. Korea United Pharm PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 52. Korea United Pharm Recent Developments/Updates
 Table 53. The Menarini Group Basic Information, Manufacturing Base and Competitors
 Table 54. The Menarini Group Major Business
 Table 55. The Menarini Group PDE-3 Inhibitors Product and Services
 Table 56. The Menarini Group PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 57. The Menarini Group Recent Developments/Updates
 Table 58. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 59. Pfizer Major Business
 Table 60. Pfizer PDE-3 Inhibitors Product and Services
 Table 61. Pfizer PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 62. Pfizer Recent Developments/Updates
 Table 63. Sanofi Basic Information, Manufacturing Base and Competitors
 Table 64. Sanofi Major Business
 Table 65. Sanofi PDE-3 Inhibitors Product and Services
 Table 66. Sanofi PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 67. Sanofi Recent Developments/Updates
 Table 68. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 69. Qilu Pharmaceutical Major Business
 Table 70. Qilu Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 71. Qilu Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 72. Qilu Pharmaceutical Recent Developments/Updates
 Table 73. Yabao Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 74. Yabao Pharmaceuticals Major Business
 Table 75. Yabao Pharmaceuticals PDE-3 Inhibitors Product and Services
 Table 76. Yabao Pharmaceuticals PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 77. Yabao Pharmaceuticals Recent Developments/Updates
 Table 78. Lunan Better Pharmaceutical Basic Information, Manufacturing Base and Competitors
 Table 79. Lunan Better Pharmaceutical Major Business
 Table 80. Lunan Better Pharmaceutical PDE-3 Inhibitors Product and Services
 Table 81. Lunan Better Pharmaceutical PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 82. Lunan Better Pharmaceutical Recent Developments/Updates
 Table 83. Yangtze River Pharmaceuticals Basic Information, Manufacturing Base and Competitors
 Table 84. Yangtze River Pharmaceuticals Major Business
 Table 85. Yangtze River Pharmaceuticals PDE-3 Inhibitors Product and Services
 Table 86. Yangtze River Pharmaceuticals PDE-3 Inhibitors Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)
 Table 87. Yangtze River Pharmaceuticals Recent Developments/Updates
 Table 88. Global PDE-3 Inhibitors Sales Quantity by Manufacturer (2020-2025) & (K Units)
 Table 89. Global PDE-3 Inhibitors Revenue by Manufacturer (2020-2025) & (USD Million)
 Table 90. Global PDE-3 Inhibitors Average Price by Manufacturer (2020-2025) & (US$/Unit)
 Table 91. Market Position of Manufacturers in PDE-3 Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
 Table 92. Head Office and PDE-3 Inhibitors Production Site of Key Manufacturer
 Table 93. PDE-3 Inhibitors Market: Company Product Type Footprint
 Table 94. PDE-3 Inhibitors Market: Company Product Application Footprint
 Table 95. PDE-3 Inhibitors New Market Entrants and Barriers to Market Entry
 Table 96. PDE-3 Inhibitors Mergers, Acquisition, Agreements, and Collaborations
 Table 97. Global PDE-3 Inhibitors Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR
 Table 98. Global PDE-3 Inhibitors Sales Quantity by Region (2020-2025) & (K Units)
 Table 99. Global PDE-3 Inhibitors Sales Quantity by Region (2026-2031) & (K Units)
 Table 100. Global PDE-3 Inhibitors Consumption Value by Region (2020-2025) & (USD Million)
 Table 101. Global PDE-3 Inhibitors Consumption Value by Region (2026-2031) & (USD Million)
 Table 102. Global PDE-3 Inhibitors Average Price by Region (2020-2025) & (US$/Unit)
 Table 103. Global PDE-3 Inhibitors Average Price by Region (2026-2031) & (US$/Unit)
 Table 104. Global PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 105. Global PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 106. Global PDE-3 Inhibitors Consumption Value by Type (2020-2025) & (USD Million)
 Table 107. Global PDE-3 Inhibitors Consumption Value by Type (2026-2031) & (USD Million)
 Table 108. Global PDE-3 Inhibitors Average Price by Type (2020-2025) & (US$/Unit)
 Table 109. Global PDE-3 Inhibitors Average Price by Type (2026-2031) & (US$/Unit)
 Table 110. Global PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 111. Global PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 112. Global PDE-3 Inhibitors Consumption Value by Application (2020-2025) & (USD Million)
 Table 113. Global PDE-3 Inhibitors Consumption Value by Application (2026-2031) & (USD Million)
 Table 114. Global PDE-3 Inhibitors Average Price by Application (2020-2025) & (US$/Unit)
 Table 115. Global PDE-3 Inhibitors Average Price by Application (2026-2031) & (US$/Unit)
 Table 116. North America PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 117. North America PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 118. North America PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 119. North America PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 120. North America PDE-3 Inhibitors Sales Quantity by Country (2020-2025) & (K Units)
 Table 121. North America PDE-3 Inhibitors Sales Quantity by Country (2026-2031) & (K Units)
 Table 122. North America PDE-3 Inhibitors Consumption Value by Country (2020-2025) & (USD Million)
 Table 123. North America PDE-3 Inhibitors Consumption Value by Country (2026-2031) & (USD Million)
 Table 124. Europe PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 125. Europe PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 126. Europe PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 127. Europe PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 128. Europe PDE-3 Inhibitors Sales Quantity by Country (2020-2025) & (K Units)
 Table 129. Europe PDE-3 Inhibitors Sales Quantity by Country (2026-2031) & (K Units)
 Table 130. Europe PDE-3 Inhibitors Consumption Value by Country (2020-2025) & (USD Million)
 Table 131. Europe PDE-3 Inhibitors Consumption Value by Country (2026-2031) & (USD Million)
 Table 132. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 133. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 134. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 135. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 136. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Region (2020-2025) & (K Units)
 Table 137. Asia-Pacific PDE-3 Inhibitors Sales Quantity by Region (2026-2031) & (K Units)
 Table 138. Asia-Pacific PDE-3 Inhibitors Consumption Value by Region (2020-2025) & (USD Million)
 Table 139. Asia-Pacific PDE-3 Inhibitors Consumption Value by Region (2026-2031) & (USD Million)
 Table 140. South America PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 141. South America PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 142. South America PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 143. South America PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 144. South America PDE-3 Inhibitors Sales Quantity by Country (2020-2025) & (K Units)
 Table 145. South America PDE-3 Inhibitors Sales Quantity by Country (2026-2031) & (K Units)
 Table 146. South America PDE-3 Inhibitors Consumption Value by Country (2020-2025) & (USD Million)
 Table 147. South America PDE-3 Inhibitors Consumption Value by Country (2026-2031) & (USD Million)
 Table 148. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Type (2020-2025) & (K Units)
 Table 149. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Type (2026-2031) & (K Units)
 Table 150. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Application (2020-2025) & (K Units)
 Table 151. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Application (2026-2031) & (K Units)
 Table 152. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Country (2020-2025) & (K Units)
 Table 153. Middle East & Africa PDE-3 Inhibitors Sales Quantity by Country (2026-2031) & (K Units)
 Table 154. Middle East & Africa PDE-3 Inhibitors Consumption Value by Country (2020-2025) & (USD Million)
 Table 155. Middle East & Africa PDE-3 Inhibitors Consumption Value by Country (2026-2031) & (USD Million)
 Table 156. PDE-3 Inhibitors Raw Material
 Table 157. Key Manufacturers of PDE-3 Inhibitors Raw Materials
 Table 158. PDE-3 Inhibitors Typical Distributors
 Table 159. PDE-3 Inhibitors Typical Customers


List of Figures
 Figure 1. PDE-3 Inhibitors Picture
 Figure 2. Global PDE-3 Inhibitors Revenue by Type, (USD Million), 2020 & 2024 & 2031
 Figure 3. Global PDE-3 Inhibitors Revenue Market Share by Type in 2024
 Figure 4. Amrinone/Inamrinone Examples
 Figure 5. Anagrelide Examples
 Figure 6. Cilostazol Examples
 Figure 7. Dipyridamole Examples
 Figure 8. Milrinone Examples
 Figure 9. Others Examples
 Figure 10. Global PDE-3 Inhibitors Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
 Figure 11. Global PDE-3 Inhibitors Revenue Market Share by Application in 2024
 Figure 12. Hospital Examples
 Figure 13. Clinic Examples
 Figure 14. Others Examples
 Figure 15. Global PDE-3 Inhibitors Consumption Value, (USD Million): 2020 & 2024 & 2031
 Figure 16. Global PDE-3 Inhibitors Consumption Value and Forecast (2020-2031) & (USD Million)
 Figure 17. Global PDE-3 Inhibitors Sales Quantity (2020-2031) & (K Units)
 Figure 18. Global PDE-3 Inhibitors Price (2020-2031) & (US$/Unit)
 Figure 19. Global PDE-3 Inhibitors Sales Quantity Market Share by Manufacturer in 2024
 Figure 20. Global PDE-3 Inhibitors Revenue Market Share by Manufacturer in 2024
 Figure 21. Producer Shipments of PDE-3 Inhibitors by Manufacturer Sales ($MM) and Market Share (%): 2024
 Figure 22. Top 3 PDE-3 Inhibitors Manufacturer (Revenue) Market Share in 2024
 Figure 23. Top 6 PDE-3 Inhibitors Manufacturer (Revenue) Market Share in 2024
 Figure 24. Global PDE-3 Inhibitors Sales Quantity Market Share by Region (2020-2031)
 Figure 25. Global PDE-3 Inhibitors Consumption Value Market Share by Region (2020-2031)
 Figure 26. North America PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 27. Europe PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 28. Asia-Pacific PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 29. South America PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 30. Middle East & Africa PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 31. Global PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 32. Global PDE-3 Inhibitors Consumption Value Market Share by Type (2020-2031)
 Figure 33. Global PDE-3 Inhibitors Average Price by Type (2020-2031) & (US$/Unit)
 Figure 34. Global PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 35. Global PDE-3 Inhibitors Revenue Market Share by Application (2020-2031)
 Figure 36. Global PDE-3 Inhibitors Average Price by Application (2020-2031) & (US$/Unit)
 Figure 37. North America PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 38. North America PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 39. North America PDE-3 Inhibitors Sales Quantity Market Share by Country (2020-2031)
 Figure 40. North America PDE-3 Inhibitors Consumption Value Market Share by Country (2020-2031)
 Figure 41. United States PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 42. Canada PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 43. Mexico PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 44. Europe PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 45. Europe PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 46. Europe PDE-3 Inhibitors Sales Quantity Market Share by Country (2020-2031)
 Figure 47. Europe PDE-3 Inhibitors Consumption Value Market Share by Country (2020-2031)
 Figure 48. Germany PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 49. France PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 50. United Kingdom PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 51. Russia PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 52. Italy PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 53. Asia-Pacific PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 54. Asia-Pacific PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 55. Asia-Pacific PDE-3 Inhibitors Sales Quantity Market Share by Region (2020-2031)
 Figure 56. Asia-Pacific PDE-3 Inhibitors Consumption Value Market Share by Region (2020-2031)
 Figure 57. China PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 58. Japan PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 59. South Korea PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 60. India PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 61. Southeast Asia PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 62. Australia PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 63. South America PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 64. South America PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 65. South America PDE-3 Inhibitors Sales Quantity Market Share by Country (2020-2031)
 Figure 66. South America PDE-3 Inhibitors Consumption Value Market Share by Country (2020-2031)
 Figure 67. Brazil PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 68. Argentina PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 69. Middle East & Africa PDE-3 Inhibitors Sales Quantity Market Share by Type (2020-2031)
 Figure 70. Middle East & Africa PDE-3 Inhibitors Sales Quantity Market Share by Application (2020-2031)
 Figure 71. Middle East & Africa PDE-3 Inhibitors Sales Quantity Market Share by Country (2020-2031)
 Figure 72. Middle East & Africa PDE-3 Inhibitors Consumption Value Market Share by Country (2020-2031)
 Figure 73. Turkey PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 74. Egypt PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 75. Saudi Arabia PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 76. South Africa PDE-3 Inhibitors Consumption Value (2020-2031) & (USD Million)
 Figure 77. PDE-3 Inhibitors Market Drivers
 Figure 78. PDE-3 Inhibitors Market Restraints
 Figure 79. PDE-3 Inhibitors Market Trends
 Figure 80. Porters Five Forces Analysis
 Figure 81. Manufacturing Cost Structure Analysis of PDE-3 Inhibitors in 2024
 Figure 82. Manufacturing Process Analysis of PDE-3 Inhibitors
 Figure 83. PDE-3 Inhibitors Industrial Chain
 Figure 84. Sales Channel: Direct to End-User vs Distributors
 Figure 85. Direct Channel Pros & Cons
 Figure 86. Indirect Channel Pros & Cons
 Figure 87. Methodology
 Figure 88. Research Process and Data Source

Companies Mentioned

Hikma Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Viatris
Otsuka Pharmaceutical
Sawai Pharmaceutical
Eurofarma
Italfarmaco
Korea United Pharm
The Menarini Group
Pfizer
Sanofi
Qilu Pharmaceutical
Yabao Pharmaceuticals
Lunan Better Pharmaceutical
Yangtze River Pharmaceuticals